Mutagenicity assay in Salmonella and in vivo sister chromatid exchange in bone marrow cells of mice for four pyrazolone derivatives

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 420, Issue 1-3, 1998, Pages 15-25

  Giri, A K ^a   Mukhopadhyay, A ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Antipyrine; Dipyrone; In vitro; In vivo; Mouse; Mutagenicity; Oxyphenbutazone; Phenylbutazone; Salmonella; Sister chromatid exchange

Indexed keywords

DIPYRONE; OXYPHENBUTAZONE; PHENAZONE; PHENYLBUTAZONE; PYRAZOLONE DERIVATIVE;

AMES TEST; ANIMAL CELL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DRUG TOXICITY; GENOTOXICITY; IN VITRO STUDY; MOUSE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; SALMONELLA; SISTER CHROMATID EXCHANGE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPYRINE; BONE MARROW CELLS; DIPYRONE; LIVER; MALE; MICE; MUTAGENICITY TESTS; OXYPHENBUTAZONE; PHENYLBUTAZONE; PYRAZOLES; PYRAZOLONES; RATS; SALMONELLA; SISTER CHROMATID EXCHANGE;

SALMONELLA;

EID: 0032420220     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5718(98)00138-7     Document Type: Article

References (49)

1. Mauer E.F. The toxic effects of phenylbutazone (butazolidin): review of the literature and report of the 23 deaths following its use. New Engl. J. Med. 253:1955;404-410.
2. D.M. Woodbury, E. Fingl, Analgesic, antipyretic, anti-inflammatory agents and drugs employed in the therapy of gout, in: L.S. Goodman, A. Gilman (Eds.), The Pharmacological Basis of Therapeutics, Macmillan Publishing, New York, 1975, pp. 339-341.
3. Greenstone M., Harhey B., Gabriel R., Bevan G. Acute nephrotic syndrome with reversible renal failure after phenylbutazone. Br. Med. J. 282:1981;950-951.
4. Chaplin S. Bone marrow depression due to mainser in, phenylbutazone, oxyphenylbutazone and chloramphenicol. Adv. Drug React. Acute Poisoning Rev. 5:1986;97-136.
5. Drug Facts and Comparisons, B.R. Olin (Editor in Chief) Facts and Comparisons. A Woltex Kluwer, St. Louis, MO, 1995, pp. 1284-1288.
6. Warsef N.W. Teratogenicity of phenylbutazone in mice. Bull. Zool. Soc. Egypt. 29:1979;16-21.
7. Schardein J.L., Blatz A.T., Woosley E.T., Kaump D.H. Reproduction studies on sodium meclofenamate in comparison to aspirin and phenylbutazone. Toxicol. Appl. Pharmacol. 15:1969;46-55.
8. McCann J., Ames B.N. Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals, discussion. Proc. Natl. Acad. Sci. 73:1976;950-954.
9. McCann J., Choi E., Yamasaki E., Ames B.N. Detection of carcinogens as mutagens in Salmonella/microsome test: assay of 300 chemicals. Proc. Natl. Acad. Sci. 72:1975;5135-5139.
10. Pentiah P.R., Reddy P.P., Reddi O.S. Induction of micronuclei in bone marrow cells of mice treated with phenylbutazone. Ind. J. Exp. Biol. 18:1980;869-871.
11. Vormittag W., Kolarz G. Chromosome tests before and after infusion therapy with phenylbutazone. Arzneim. Forsch. 29:1979;1163-1168.
12. Muller D., Strasser F. Comparative studies on the Chinese bone marrow after treatment with phenylbutazone and cyclophosphamide. Mutation Res. 13:1971;377-382.
13. Jensen M.K. Phenylbutazone, chloramphenicol and mammalian chromosomes. Humangenetik. 17:1972;61-64.
14. Charles D., Leonard A. Mutagenicity tests with phenylbutazone in mammals. Toxicol. Lett. 2:1978;225-230.
15. Bignami M., Morpurgo G., Pagliani R., Carere A., Conti G., Di Giuseppe G. Nondisjunction and crossing over induced by pharmaceutical drugs in Aspergillus nidulans. Mutation Res. 26:1974;159-170.
16. International Agency for Research on Cancer, Monograph on the Evaluation of the Carcinogenic Risk of Chemicals to Man: Some Miscellaneous Pharmaceutical Substances, Lyon, France, 13, 1977, pp. 183-200.
17. Kari F., Bucher J., Haseman J., Euistis S., Huff J. Long term exposure to the anti-inflammatory agent phenylbutazone induces kidney tumors in rats and liver tumors in mice. Natl. Inst. Environ. Health Sci. 86:1995;252-263.
18. Kuboyama N., Fujii A. Mutagenicity of analgesics, their derivatives and anti-inflammatory drugs with S9 mix of several animal species. J. Nihon Univ. Sch. Dent. 34:1992;183-195.
19. Klein W., Kocsis F., Scherer G., Altmann H.Z. Experimental effects of oxyphenbutazone and prednisolone on the DNA metabolism in Syrian hamsters. Rheumatology. 39:1980;301-308.
20. Granberg-Ohman I., Johansson S., Hjerpe A. Sister chromatid exchanges and chromosomal aberrations in rats treated with phenacetin, phenazone and caffeine. Mutation Res. 79:1980;13-18.
21. Rao S.G., Krishna G. Drug-nitrite interactions: formation of N-nitroso, C-nitroso and nitro compounds from sodium nitrite and various drug under physiological conditions. J. Pharmaceutical Sci. 64:1975;1579-1581.
22. Johansson S.L. Carcinogenicity of analgesics: long term treatment of Sprague-Dawley rats with phenacetin, phenazone, caffeine and paracetamol (acetamidophen). Int. J. Cancer. 27:1981;521-529.
23. Johansson S.L., Anderstrom C. The influence of antipyrine on N-[4-(5-nitro-2,furyl)-2-thiazolyl]-formamide induced urinary tract carcinogenesis. Carcinogenesis. 9:1988;783-787.
24. Kumagain H., Kawaura A., Shibata M., Otsuka H. Carcinogenicity of dipyrone in C57B2/6XC34) F1 mice. J. Natl. Cancer Inst. 71:1983;1295-1297.
25. Donabauer H.H., Kief H., Kramer M., Krieg K., Mayer D., Schutz E. Investigations on the carcinogenicity of dipyrone in rats. Toxicol. Appl. Pharmacol. 81:1985;443-451.
26. Sylianco C.Y.L. Some interactions affecting the mutagenicity potential of dipyrone, hexachlorophene, thioden and malathion. Mutation Res. 53:1978;271.
27. Izumi K., Sano N., Otsuka H., Kinouchi T., Ohnishi Y. Tumor promoting potential in male F344 rats and mutagenicity in Salmonella typhimurium of dipyrone. Carcinogenesis. 12:1991;1221-1225.
28. Reddy A., Subramanyam S. In vivo cytogenetic effects of metamizole on germ cells of mice. Caryologia. 36:1983;251-258.
29. Mikheev V.S., Togo E.F., Sivenkov E.S. Effect of immobilization of analgin in polyvinylcohol on its mutagenicity in mice. Genetika. 29:1993;785-790.
30. Giri A.K. Genetic toxicology of paracetamol and aspirin - a review. Mutation Res. 296:1993;199-210.
31. Giri A.K., Lu L.J.W. Genetic damage and the inhibition of 7,12-dimethyl-benz[a]anthracene induced genetic damage by the phytoestrogens, genistein and diadzein, in female ICR mice. Cancer Lett. 95:1995;125-133.
32. Giri A.K., Banerjee S. Genetic toxicology of four commonly used benzodiazepines: a review. Mutation Res. 339:1996;1-14.
33. Giri A.K., Messerly E.A., Sinsheimer J.E. Sister chromatid exchange and chromosome aberrations for four aliphatic epoxides in mice. Mutation Res. 224:1989;253-261.
34. Giri A.K., Adhikari N., Khan K.A. Comparative genotoxicity of six salicylic acid derivatives in bone marrow cells of mice. Mutation Res. 370:1996;1-9.
35. Philipose B., Singh R., Khan K.A., Giri A.K. Comparative mutagenic and genotoxic effects of three propionic acid derivatives ibuprofen, ketoprofen and naproxen. Mutation Res. 393:1997;123-131.
36. Ames B.N., Durston W.E., Yamasaki E., Lee F.D. Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc. Natl. Acad. Sci. (USA). 70:1973;2081-2285.
37. Garner R.C., Miller E.C., Miller J.A. Liver microsomal metabolism of aflatoxin B1 to a reactive derivative toxic to Salmonella typhimurium TA1530. Cancer Res. 32:1972;2058-2066.
38. Maron D.M., Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutation Res. 113:1983;173-215.
39. McFee A.F., Lowe K., San Sebastian J.R. Improved sister chromatid differentiation using paraffin coated bromodeoxyuridine tablets in mice. Mutation Res. 119:1983;83-88.
40. Preston R.J., Dean B.J., Galloway S., Holden H., McFee A.F., Shelby M. Mammalian in vivo cytogenetic assays. Analysis of chromosome aberrations in bone marrow cells. Mutation Res. 198:1987;157-165.
41. World Health Organization, Environmental Health Criteria 51, Guide to Short-Term Test for Detecting Mutagenic and Carcinogenic Chemicals, WHO, Geneva, 1985, pp. 100-114.
42. Ivett J.L., Tice R.R. Average generation time: a new method for analyzing cellular proliferation kinetics based on bromodeoxyuridine-dependent chromosome differential staining patterns. Environ. Mutagen. 4:1982;358-365.
43. Dunnett C.W. A multiple comparison procedure for comparing several treatments with the control. J. Am. Stat. Assoc. 50:1955;1096-1121.
44. Machemer L., Hess R. Comparative dominant lethal studies with phenylbutazone, thio-TEPA and MMS in mouse. Experientia. 27:1971;1050-1052.
45. Machemer L., Hess R. Induced dominant lethals in female mice: effects of triaziquone and phenylbutazone. Experientia. 29:1973;190-192.
46. Smith A.L., Lodge J.R., Link R.P. In vitro effects of phenylbutazone on equine chromosomes. Vet. Rec. 104:1979;195-196.
47. Arisawa M., Fujiu M., Suhara Y., Maruyama H.B. Differential mutagenicity of reaction products of various pyrazolones with nitrite. Mutation Res. 57:1978;287-296.
48. Ohta T., Asabe Y., Takitani S. Identification of mutagenic nitrosation products of antipyrine and evaluation of their formation under model stomach conditions. Chem. Pharm. Bull. 34:1986;3866-3872.
49. Parisis D.M., Rao G.S. Mutagenicity of 4-aminoantipyrine and 4-nitrosoantipyrine, the C-nitroso-derivative of antipyrine. Mutation Res. 206:1988;317-326.